

Applicant(s): Suthanthiran, et al.
Application Serial No.: 10/627,408
Filing Date: July 25, 2003
Our Docket: 955-10 P/CON/DIV
Reply to Final Office Action of May 3, 2007
Page 2 of 9

AMENDMENTS

IN THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously presented) A method for reducing formation, progression or metastasis of a neoplasm in a human in need thereof, the method comprising treating the human with an effective amount of an angiotensin II receptor type AT1 antagonist, wherein the treatment is not part of a chemotherapy or radiation therapy treatment regimen.
2. (Cancelled)
3. (Withdrawn) The method according to claim 2, wherein the angiotensin II antagonist blocks the angiotensin II-binding site of an angiotensin II receptor.
4. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor is an Angiotensin Converting Enzyme (ACE) inhibitor.
5. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor comprises an anti-angiotensin II antibody.
6. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor comprises an anti-angiotensin I antibody.
7. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor comprises an anti-angiotensinogen antibody.
8. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor is a protein or peptide.

Applicant(s): Suthanthyran, et al.
Application Serial No.: 10/627,408
Filing Date: July 25, 2003
Our Docket: 955-10 P/CON/DIV
Reply to Final Office Action of May 3, 2007
Page 3 of 9

9. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor blocks the production of angiotensin I.
10. (Withdrawn) The method according to claim 9, wherein the angiotensin II inhibitor is a renin inhibitor.
11. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor blocks the expression of angiotensinogen.
12. (Withdrawn) The method according to claim 1, wherein the angiotensin II inhibitor is an antibody or an antibody fragment specific for the angiotensin II receptor.
13. (Original) The method according to claim 1, wherein the angiotensin II inhibitor is a small molecule.
14. (Cancelled)
15. (New) A method according to claim 1, wherein the human is a transplant recipient.
16. (New) A method according to claim 1, wherein the human is an autoimmune patient.
17. (New) A method for reducing formation, progression or metastasis of a neoplasm associated with immunosuppressive therapy in a human in need thereof, the method comprising treating the human with an effective amount of an angiotensin II receptor type AT1 antagonist, wherein the treatment is not part of a chemotherapy or radiation therapy treatment regimen.
18. (New) A method according to claim 17, wherein the human is a transplant recipient.

Applicant(s): Suthanthiran, et al.
Application Serial No.: 10/627,408
Filing Date: July 25, 2003
Our Docket: 955-10 P/CON/DIV
Reply to Final Office Action of May 3, 2007
Page 4 of 9

19. (New) A method according to claim 17, wherein the human is an autoimmune patient.
20. (New) A method according to claim 1, wherein the neoplasm is a tumor of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, and liver.